Biosimilar Infliximab Switching is Not Associated with Adverse Outcomes: A Real-World Effectiveness Analyses in a National US Cohort of US Military Veterans with Inflammatory Bowel Disease

被引：0
|
作者：
Hou, J. K. [1 ]
Pham, C. [2 ]
Sansgiry, S. [3 ]
Modi, V. [2 ]
Waljee, A. K. [4 ]
机构：
[1] Baylor Coll Med, Sect Gastroenterol, 5207 Contour Pl, Houston, TX USA
[2] Baylor Coll Med, Med, Houston, TX USA
[3] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Med, Houston, TX USA
[4] Ann Arbor VA Univ Michigan, Med, Ann Arbor, VA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P750
引用
收藏
页码：880 / 881
页数：2
相关论文
共 50 条
  • [41] Comparative Effectiveness of Vedolizumab vs. Infliximab Induction Therapy in Ulcerative Colitis: Experience of a Real-World Cohort at a Tertiary Inflammatory Bowel Disease Center
    Allamneni, Chaitanya
    Venkata, Krishna
    Yun, Huifeng
    Xie, Fenglong
    DeLoach, Lindsey
    Malik, Talha A.
    GASTROENTEROLOGY RESEARCH, 2018, 11 (01) : 41 - 45
  • [42] Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)
    Bincy Abraham
    Bertus Eksteen
    Khan Nedd
    Hrishikesh Kale
    Dipen Patel
    Jennifer Stephens
    Ahmed Shelbaya
    Richard Chambers
    Arif Soonasra
    Advances in Therapy, 2022, 39 : 2109 - 2127
  • [43] COMPARISON OF REAL-WORLD TREATMENT OUTCOMES WITH INFLIXIMAB VERSUS VEDOLIZUMAB IN BIOLOGIC-NAIVE PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Latremouille-Viau, Dominick
    Burne, Rebecca
    Shi, Sherry
    Adsul, Shashi
    Patel, Haridarshan
    GASTROENTEROLOGY, 2019, 156 (06) : S638 - S639
  • [44] Comparison of Real-World Treatment Outcomes With Vedolizumab Versus Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease
    Patel, Haridarshan
    Latremouille-Viau, Dominick
    Burne, Rebecca
    Shi, Sherry
    Adsul, Shashi
    CROHNS & COLITIS 360, 2019, 1 (02)
  • [45] Microscopic Colitis Is Associated With a Significantly Increased Risk of Inflammatory Bowel Disease in the US Population: A National Cohort Study
    Chen, Bing
    El Halabi, Maan
    Mahmoud, Omar
    Nelson, Frank
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S422 - S422
  • [46] USE OF DIFFERENT STATISTICAL APPROACHES TO COMPARE REAL-WORLD OUTCOMES ASSOCIATED WITH VEDOLIZUMAB VERSUS INFLIXIMAB IN BIOLOGIC-NAIVE PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Latremouille-Viau, D.
    Burne, R.
    Shi, S.
    Patel, H.
    VALUE IN HEALTH, 2019, 22 : S178 - S178
  • [47] Outcomes of angioembolization and nephrectomy for renal angiomyolipoma associated with tuberous sclerosis complex: a real-world US national study
    Sun, Peter
    Liu, Jamae
    Charles, Hearns
    Hulbert, John
    Bissler, John
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (05) : 821 - 827
  • [48] Comparison of real-world treatment outcomes with infliximab vs. vedolizumab in biologic-naive patients with inflammatory bowel disease
    Latremouille-Viau, D.
    Burne, R.
    Shi, S.
    Adsul, S.
    Patel, H.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S295 - S296
  • [49] Sarcopenia is associated with worse outcomes in patients with inflammatory bowel disease: insights from US national hospitalization data
    Kohli, Isha
    Thind, Nuhar
    Bhalla, Akshita
    Attri, Amitpal
    Bhupal, Sahiljot Singh
    Sohal, Aalam
    Yang, Juliana
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 37 (01) : 55 - 61
  • [50] Real-World Data on the Treatment of chronic inflammatory Bowel Diseases Infliximab Therapy after Switching to Biosimilar SB2 also long term and contractually effective
    不详
    VISCERAL MEDICINE, 2021, 37 (03)
12345